BioSpectrum
the business of Bio & Health Sciences
ASIA EDITION

China's AsymBio secures $184 M capital injection to support long-term growth

August 5, 2026 | News

AsymBio has continued to invest in R&D platforms, GMP manufacturing lines and high-potency, high-containment facilities



AsymBio, a China-based biologics-focused Contract Development and Manufacturing Organization (CDMO) and a subsidiary of Asymchem Group, has announced a total capital injection of RMB 1.2397 billion (approximately $184 million) into AsymBio by Asymchem Group, Hillhouse Qirui and other investors.

Upon completion of the capital increase, Asymchem Group's shareholding in AsymBio will increase to 83.4965%. The transaction reflects strong confidence in AsymBio's differentiated CDMO strategy and its long-term potential to support global pharmaceutical and biotechnology companies advancing complex biologics programmes.

Of the total capital injection, Asymchem Group will contribute RMB 1.05 billion (approximately $156 million), while Hillhouse Qirui will contribute RMB 177 million (approximately $26 million).

Hillhouse Qirui's significant participation underscores its long-term confidence in AsymBio and the biologics CDMO sector. Hillhouse has a long track record of investing across the biopharmaceutical value chain and the broader global healthcare sector. Its investment aligns with Asymchem Group's differentiated, one-stop, end-to-end CDMO strategy.

Globally, pipelines involving antibody-drug conjugates (ADCs), novel drug conjugates (NDCs), and bispecific and multispecific antibodies are advancing rapidly into clinical development. At the same time, outsourcing demand from biotech companies and large pharmaceutical companies in China and global markets continues to expand.

AsymBio's growth momentum is evident in its operating performance. The company generated approximately RMB 470 million (approximately $70 million) in revenue in 2025, with first-quarter 2026 revenue exceeding RMB 140 million (approximately $21 million).